Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.
Behr, Paulo Eduardo Ballvé; Moriguchi, Emilio Hideyuki; Castro, Iran; Bodanese, Luiz Carlos; Dutra, Oscar Pereira; Leães, Paulo Ernesto; Pimentel Filho, Pedro.
Arq Bras Cardiol
; 111(1): 104-108, 2018 07.
Artigo em Inglês, Português | MEDLINE | ID: mdl-30110052
Evolocumab and alirocumab: exploring original procurement models to manage the reimbursement of these innovative treatments.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Rush to protect lucrative antibody patents kicks into gear.
A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
PCSK9 Inhibitors: Economics and Policy.
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
Cholesterol Management in the Era of PCSK9 Inhibitors.
Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals.